Skip to content
Company Analysis

Scilex Holding Company SCLXW

A comprehensive view of key metrics, scores, and financial health for Scilex Holding Company

Overview of Scilex Holding Company

SCLXW NCM
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech
Scilex Holding Company (SCLXW), in the Drug Manufacturers - General industry, last closed at $0.21, about 0.0% overvalued vs fair value, ranked 1128/1145 in sector.
Metrics Rev Growth -46.5% ROE 179.2% Gross Margin 65.0%
USD 0.21
54.41%
(Delayed)
• Vol 90d: 140.3%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Completeness: 56%
Confidence: 68%
Updated: Jul 5
Top Beats
No strong beats yet

Quick Facts

Website https://www.scilexholding.com
HQ Palo Alto, CA
Employees 30
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$30.3M
-46.5%%
Gross Profit
$19.7M
-50.7%%
R&D Expense
$20.7M
114.8%%
Operating Income (EBIT)
$-362.6M
-411.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
68.5%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Scilex Holding Company's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
36
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
25
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 81% Coverage
Trade-Off Triangle Visualization A ternary plot showing SCLXW's balance between Growth (16.6%), Profitability (48.4%), and Safety (35.0%). Growth 17% Safety 35% Profitability 48%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

14th percentile vs peers
14
Key Signals
Revenue CAGR 3Y -7.3% 22p Rev Growth YoY -46.5% 7p
Strengths
  • D/E Ratio in top 20% of peers (-59.8%, 87th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • ROIC in top 20% of peers (2.76, 99th percentile)
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 14)
  • Rev Growth YoY in bottom 20% of peers (-46.5%)

Profitability

41th percentile vs peers
42
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

30th percentile vs peers
30
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Scilex Holding Company.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000